Chen AA - Search Results

1

Antitumor activity of a recombinant soluble ectodomain of mutant human fibroblast growth factor receptor-2 IIIc.

Wang J, Liu XT, Huang H, Xiao G, Zhou ZY, Chen Y, Yu ZH, He SL, Chen AA, Wang DD, He Y, Zhang ZC, Hong A. Wang J, et al. Among authors: chen aa, chen y. Mol Cancer Ther. 2011 Sep;10(9):1656-66. doi: 10.1158/1535-7163.MCT-11-0163. Epub 2011 Jul 12. Mol Cancer Ther. 2011. PMID: 21750221

2

Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice.

Yu ZH, Wang DD, Zhou ZY, He SL, Chen AA, Wang J. Yu ZH, et al. Among authors: chen aa. Biol Pharm Bull. 2012;35(5):731-6. doi: 10.1248/bpb.35.731. Biol Pharm Bull. 2012. PMID: 22687409 Free article.

3

Inhibitory effect of BMP-2 on the proliferation of breast cancer cells.

Chen A, Wang D, Liu X, He S, Yu Z, Wang J. Chen A, et al. Mol Med Rep. 2012 Sep;6(3):615-20. doi: 10.3892/mmr.2012.962. Epub 2012 Jun 21. Mol Med Rep. 2012. PMID: 22735990

4

BMP-2 induces EMT and breast cancer stemness through Rb and CD44.

Huang P, Chen A, He W, Li Z, Zhang G, Liu Z, Liu G, Liu X, He S, Xiao G, Huang F, Stenvang J, Brünner N, Hong A, Wang J. Huang P, et al. Cell Death Discov. 2017 Jul 17;3:17039. doi: 10.1038/cddiscovery.2017.39. eCollection 2017. Cell Death Discov. 2017. PMID: 28725489 Free PMC article.

5

How BMP-2 induces EMT and breast cancer stemness through Rb and CD44?

Zhang G, Huang P, Chen A, He W, Li Z, Liu G, Wang J. Zhang G, et al. Cell Death Dis. 2018 Jan 16;9(2):20. doi: 10.1038/s41419-017-0037-0. Cell Death Dis. 2018. PMID: 29339728 Free PMC article. No abstract available.

6

SAGE1: a Potential Target Antigen for Lung Cancer T-Cell Immunotherapy.

Zhang Y, Yu X, Liu Q, Gong H, Chen AA, Zheng H, Zhong S, Li Y. Zhang Y, et al. Among authors: chen aa. Mol Cancer Ther. 2021 Nov;20(11):2302-2313. doi: 10.1158/1535-7163.MCT-21-0203. Epub 2021 Aug 31. Mol Cancer Ther. 2021. PMID: 34465596

7

High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells.

Liang Z, Li Y, Tian Y, Zhang H, Cai W, Chen A, Chen L, Bao Y, Xiang B, Kan H, Li Y. Liang Z, et al. Cancer Lett. 2019 Apr 10;447:164-173. doi: 10.1016/j.canlet.2019.01.016. Epub 2019 Jan 21. Cancer Lett. 2019. PMID: 30677447

8

Corrigendum to 'High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells' [Cancer Lett. 447 (2019) 164-173].

Liang Z, Li Y, Tian Y, Zhang H, Cai W, Chen A, Chen L, Bao Y, Xiang B, Kan H, Li Y. Liang Z, et al. Cancer Lett. 2019 Jun 28;452:268-269. doi: 10.1016/j.canlet.2019.03.026. Epub 2019 Mar 28. Cancer Lett. 2019. PMID: 30929810 No abstract available.

9

ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression.

Zhang H, Li Y, Liu X, Liang Z, Yan M, Liu Q, Chen A, Bao Y, Zhou C, Li S, Yee C, Li Y. Zhang H, et al. Immunology. 2018 Oct;155(2):238-250. doi: 10.1111/imm.12954. Epub 2018 Jun 14. Immunology. 2018. PMID: 29791021 Free PMC article.

10

Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma.

Chen A, Yu Z, Ma N, Lu X, Zhang Y, Xu W, Wang Y, Xie J, Qin Y, Mo G, Wu S, Hou J, Zhu W. Chen A, et al. Cancer Immunol Immunother. 2024 Feb 13;73(3):49. doi: 10.1007/s00262-024-03628-2. Cancer Immunol Immunother. 2024. PMID: 38349553 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

146 results

Search Page

Filters